Profile
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing products that fulfill unmet medical needs. MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG—the first and only FDA-approved once-daily amoxicillin.

We have developed a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. MOXATAG is our first product utilizing our proprietary PULSYS technology. While MiddleBrook is currently focused on the anti-infective arena, we see opportunities for PULSYS products in the anti-fungal, antiviral, and oncology markets as well.

Featured Documents

   Third Quarter 2009 Results Conference Call Slides

   Annual Report on Form 10-K

Recent Releases

Apr 30, 2010
MiddleBrook Pharmaceuticals Files for Chapter 11 Bankruptcy Protection

Mar 23, 2010
MiddleBrook Pharmaceuticals Announces Board of Directors Resignations

View all releases »

Stock Chart
3 Mo.   6 Mo.   1 Yr.
Stock Quote
MiddleBrook Pharmaceuticals, Inc.
Price:	0.13
Change:	+ 0.01
Day High:	0.20
Day Low:	0.12
Volume:	9,054,900
Delayed at least 20 minutes. Provided by eSignal.

Contact Information

Investor Relations
MiddleBrook Pharmaceuticals
7 Village Circle, Suite 100
Westlake, TX 76262
Phone: (817) 837-1200
Fax: (817) 582-0400
ir@middlebrookpharma.com